Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Antioxidants (Basel) ; 11(5)2022 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-35624758

RESUMO

Selenium (Se) role in obesity is not clear. In addition, information on Se's role in male physiology, specifically in obesity, is scarce. We conducted this study to evaluate the efficacy of Se supplementation, specifically during puberty until young adulthood, against obesity-induced deregulation of metabolic, cellular, and epigenetic parameters in epididymal fat and/or sperm cells in a rat model. High-fat-diet consumption by male rats during puberty and young adulthood significantly increased body weight, adipocyte size, oxidative stress, deregulated expression of genes associated with inflammation (Adiponectin, IL-6, TNF-α), adipogenesis (CEBPα), estrogen biosynthesis (CYP19) and epigenetic processes in epididymal adipose tissue (Dnmt3a), as well as altered microRNA expression vital for spermatogenesis in sperm cells (miR-15b and miR-497). On the other hand, Se supplementation significantly decreased oxidative stress and mitigated these molecular/epigenetic alterations in epididymal adipose tissue or sperm cells. Our results indicate that selenium supplementation during puberty/young adulthood could improve male physiology in the context of obesity. In addition, it suggests that Se could potentially positively affect offspring health.

2.
Food Chem Toxicol ; 134: 110813, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31505237

RESUMO

Zinc is required for fetal development and is involved in key processes associated with breast carcinogenesis. We evaluated whether maternal zinc deficiency or supplementation during gestation influences female offspring susceptibility to breast cancer in adulthood. C57BL/6 mice consumed during gestation control (30 p.p.m. zinc), zinc-deficient (8 p.p.m) or zinc-supplemented (45 p.p.m.) diets. Maternal zinc supplementation increased in female mice offspring the incidence of chemically-induced mammary adenocarcinomas that were heavier, compared to control group. This was accompanied by a decreased number of terminal end buds, increased cell proliferation and apoptosis, and increased tumor suppressors p21, p53 and Rassf1, Zfp382 and Stat3 expression in mammary glands, as well as increased zinc status. Although maternal zinc deficiency did not alter the incidence of these lesions, it also induced heavier mammary adenocarcinomas, compared to control group. These effects were accompanied by a decreased number of terminal end buds, increased proto-oncogenes c-Myc and Lmo4 expression and H3K9Me3 and H4K20Me3 epigenetic marks in mammary glands of offspring, and decreased zinc status and increased levels of oxidative marker malondialdehyde. The data suggest that both maternal zinc deficiency and supplementation during gestation programmed increased breast cancer susceptibility in adult mice offspring following a J-shaped pattern through distinct mechanisms.


Assuntos
Deficiências Nutricionais/complicações , Suplementos Nutricionais , Neoplasias Mamárias Experimentais/etiologia , Zinco/administração & dosagem , Zinco/deficiência , Animais , Apoptose , Proliferação de Células , Feminino , Perfilação da Expressão Gênica , Masculino , Neoplasias Mamárias Experimentais/genética , Neoplasias Mamárias Experimentais/patologia , Camundongos , Camundongos Endogâmicos C57BL , Gravidez , Proteínas Proto-Oncogênicas p21(ras)/metabolismo , Proto-Oncogenes , Proteína Supressora de Tumor p53/metabolismo
3.
Nutrition ; 27: 891-896, 2011.
Artigo em Inglês | SES-SP, SESSP-ISPROD, SES-SP, SESSP-ISACERVO | ID: biblio-1064960

RESUMO

Objective: Alterations in selenium (Se) status may result in suboptimal amounts of selenoproteins, which have been associated with increased oxidative stress levels. The Pro198Leu polymorphism at the glutathione peroxidase-1 (GPx1) gene is supposed to be functional. The response of Se status, GPx activity, and levels of DNA damage to a Se supplementation trial between the genotypes related to that polymorphism was investigated...


Assuntos
Feminino , Humanos , DNA , Bertholletia , Ingestão de Alimentos , Glutationa Peroxidase , Polimorfismo Genético , Selênio , Obesidade Mórbida
4.
J Nutrigenet Nutrigenomics ; 5(2): 72-80, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22677746

RESUMO

BACKGROUND/AIMS: Oxidative stress plays a central role in Alzheimer's disease (AD). Pro198Leu cytosolic glutathione peroxidase (GPx1) polymorphism seems to be associated with a lower activity of this enzyme, but there are no studies with AD patients. Thus, the aim was to determine the frequency of the GPx1 Pro198Leu polymorphism in AD patients and to verify its relation to glutathione peroxidase (GPx) activity and selenium (Se) status. METHODS: The study was carried out in a group of AD elderly (n = 28) compared to a control group (n = 29). Blood Se concentrations were measured through hydride generation atomic absorption spectroscopy. GPx activity was determined using a commercial kit, and the polymorphism using amplified DNA sequencing. RESULTS: The distribution of genotypes was not different between groups. The variant allele frequency was 0.179 (AD group) and 0.207 (control group). Although no differences regarding GPx activity were found between individuals with different genotypes, lower blood Se levels were found in Pro/Pro AD patients compared to Pro/Pro control subjects, which was not found in the Pro/Leu groups. Moreover, the association between the erythrocyte Se concentration and GPx activity was affected by the Pro198Leu genotype. CONCLUSIONS: Results indicate that this polymorphism had apparently affected Se status in AD patients and that more studies in this field are necessary.


Assuntos
Doença de Alzheimer/genética , Glutationa Peroxidase/genética , Leucina/genética , Prolina/genética , Selênio/sangue , Idoso , Doença de Alzheimer/enzimologia , Sequência de Bases , Brasil , Estudos de Casos e Controles , Primers do DNA , Feminino , Glutationa Peroxidase/sangue , Glutationa Peroxidase/química , Humanos , Masculino , Reação em Cadeia da Polimerase , Polimorfismo de Nucleotídeo Único , Glutationa Peroxidase GPX1
5.
J Nutr Biochem ; 23(6): 557-66, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21764281

RESUMO

Propolis is a polyphenol-rich resinous substance extensively used to improve health and prevent diseases. The effects of polyphenols from different sources of propolis on atherosclerotic lesions and inflammatory and angiogenic factors were investigated in LDL receptor gene (LDLr-/-) knockout mice. The animals received a cholesterol-enriched diet to induce the initial atherosclerotic lesions (IALs) or advanced atherosclerotic lesions (AALs). The IAL or AAL animals were divided into three groups, each receiving polyphenols from either the green, red or brown propolis (250 mg/kg per day) by gavage. After 4 weeks of polyphenol treatment, the animals were sacrificed and their blood was collected for lipid profile analysis. The atheromatous lesions at the aortic root were also analyzed for gene expression of inflammatory and angiogenic factors by quantitative real-time polymerase chain reaction and immunohistochemistry. All three polyphenol extracts improved the lipid profile and decreased the atherosclerotic lesion area in IAL animals. However, only polyphenols from the red propolis induced favorable changes in the lipid profiles and reduced the lesion areas in AAL mice. In IAL groups, VCAM, MCP-1, FGF, PDGF, VEGF, PECAM and MMP-9 gene expression was down-regulated, while the metalloproteinase inhibitor TIMP-1 gene was up-regulated by all polyphenol extracts. In contrast, for advanced lesions, only the polyphenols from red propolis induced the down-regulation of CD36 and the up-regulation of HO-1 and TIMP-1 when compared to polyphenols from the other two types of propolis. In conclusion, polyphenols from propolis, particularly red propolis, are able to reduce atherosclerotic lesions through mechanisms including the modulation of inflammatory and angiogenic factors.


Assuntos
Inibidores da Angiogênese/farmacologia , Aterosclerose/tratamento farmacológico , Extratos Vegetais/farmacologia , Polifenóis/farmacologia , Própole/química , Animais , Aorta/efeitos dos fármacos , Aorta/metabolismo , Aterosclerose/patologia , Aterosclerose/prevenção & controle , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Colesterol/sangue , Regulação para Baixo , Fatores de Crescimento de Fibroblastos/genética , Fatores de Crescimento de Fibroblastos/metabolismo , Inflamação/tratamento farmacológico , Inflamação/patologia , Inflamação/prevenção & controle , Metaloproteinase 9 da Matriz/genética , Metaloproteinase 9 da Matriz/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fator de Crescimento Derivado de Plaquetas/genética , Fator de Crescimento Derivado de Plaquetas/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Receptores de LDL/genética , Receptores de LDL/metabolismo , Inibidor Tecidual de Metaloproteinase-1/genética , Inibidor Tecidual de Metaloproteinase-1/metabolismo , Regulação para Cima , Molécula 1 de Adesão de Célula Vascular/genética , Molécula 1 de Adesão de Célula Vascular/metabolismo , Fatores de Crescimento do Endotélio Vascular/genética , Fatores de Crescimento do Endotélio Vascular/metabolismo
6.
Int J Cancer ; 129(9): 2073-82, 2011 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-21480218

RESUMO

Folic acid (FA) supplementation during carcinogenesis is controversial. Considering the impact of liver cancer as a public health problem and mandatory FA fortification in several countries, the role of FA supplementation in hepatocarcinogenesis should be elucidated. We evaluated FA supplementation during early hepatocarcinogenesis. Rats received daily 0.08 mg (FA8 group) or 0.16 mg (FA16 group) of FA/100 g body weight or water (CO group, controls). After a 2-week treatment, animals were subjected to the "resistant hepatocyte" model of hepatocarcinogenesis (initiation with diethylnitrosamine, selection/promotion with 2-acetylaminofluorene and partial hepatectomy) and euthanized after 8 weeks of treatment. Compared to the CO group, the FA16 group presented: reduced (p < 0.05) number of persistent and increased (p < 0.05) number of remodeling glutathione S-transferase (GST-P) positive preneoplastic lesions (PNL); reduced (p < 0.05) cell proliferation in persistent GST-P positive PNL; decreased (p < 0.05) hepatic DNA damage; and a tendency (p < 0.10) for decreased c-myc expression in microdissected PNL. Regarding all these parameters, no differences (p > 0.05) were observed between CO and FA8 groups. FA-treated groups presented increased hepatic levels of S-adenosylmethionine but only FA16 group presented increased S-adenosylmethionine/S-adenosylhomocysteine ratio. No differences (p > 0.05) were observed between experimental groups regarding apoptosis in persistent and remodeling GST-P positive PNL, and global DNA methylation pattern in microdissected PNL. Altogether, the FA16 group, but not the FA8 group, presented chemopreventive activity. Reversion of PNL phenotype and inhibition of DNA damage and of c-myc expression represent relevant FA cellular and molecular effects.


Assuntos
Transformação Celular Neoplásica/efeitos dos fármacos , Suplementos Nutricionais , Ácido Fólico/farmacologia , Neoplasias Hepáticas Experimentais/prevenção & controle , Animais , Apoptose/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/metabolismo , Quimioprevenção , Dano ao DNA , Metilação de DNA , Expressão Gênica , Genes myc , Glutationa Transferase/metabolismo , Fígado/anatomia & histologia , Fígado/metabolismo , Fígado/patologia , Neoplasias Hepáticas Experimentais/genética , Neoplasias Hepáticas Experimentais/metabolismo , Masculino , Tamanho do Órgão/efeitos dos fármacos , Lesões Pré-Cancerosas/genética , Lesões Pré-Cancerosas/metabolismo , Lesões Pré-Cancerosas/prevenção & controle , Ratos , Ratos Wistar , S-Adenosil-Homocisteína/metabolismo , S-Adenosilmetionina/metabolismo
7.
Nutrition ; 27(9): 891-6, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21208780

RESUMO

OBJECTIVE: Alterations in selenium (Se) status may result in suboptimal amounts of selenoproteins, which have been associated with increased oxidative stress levels. The Pro198Leu polymorphism at the glutathione peroxidase-1 (GPx1) gene is supposed to be functional. The response of Se status, GPx activity, and levels of DNA damage to a Se supplementation trial between the genotypes related to that polymorphism was investigated. METHODS: A randomized trial was conducted with 37 morbidly obese women. Participants consumed one Brazil nut, which provided approximately 290 µg of Se a day, for 8 wk. Blood Se concentrations, erythrocyte GPx activity, and DNA damage levels were measured at baseline and at 8 wk. The results were compared by genotypes. RESULTS: The genotype frequencies were 0.487, 0.378, and 0.135 for Pro/Pro (the wild-type genotype), Pro/Leu, and Leu/Leu, respectively. At baseline, 100% of the subjects were Se deficient, and after the supplementation, there was an improvement in plasma Se (P < 0.001 for Pro/Pro and Pro/Leu, P < 0.05 for Leu/Leu), erythrocyte Se (P = 0.00 for Pro/Pro and Pro/Leu, P < 0.05 for Leu/Leu), and GPx activity (P = 0.00 for Pro/Pro, P < 0.00001 for Pro/Leu, P < 0.001 for Leu/Leu). In addition, the Pro/Pro group showed a decrease in DNA damage after Brazil nut consumption compared with baseline (P < 0.005), and those levels were higher in Leu/Leu subjects compared with those with the wild-type genotype (P < 0.05). CONCLUSION: Consumption of one unit of Brazil nuts daily effectively increases Se status and increases GPx activity in obese women, regardless of GPx1 Pro198Leu polymorphism. However, the evaluated biomarkers showed distinct results in response to the supplementation when the polymorphism was considered.


Assuntos
Bertholletia/química , Dano ao DNA , Deficiências Nutricionais/metabolismo , Glutationa Peroxidase/metabolismo , Obesidade Mórbida/metabolismo , Polimorfismo de Nucleotídeo Único , Selênio/sangue , Adolescente , Adulto , Biomarcadores/sangue , Deficiências Nutricionais/dietoterapia , Suplementos Nutricionais , Feminino , Genótipo , Glutationa Peroxidase/genética , Humanos , Terapia Nutricional , Estado Nutricional , Nozes/química , Obesidade Mórbida/genética , Estresse Oxidativo , Selênio/deficiência , Selênio/farmacologia , Glutationa Peroxidase GPX1
8.
J Nutrigenet Nutrigenomics ; 4(5): 275-92, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22353664

RESUMO

Epigenetic processes participate in cancer development and likely influence cancer prevention. Global DNA hypomethylation, gene promoter hypermethylation and aberrant histone post-translational modifications are hallmarks of neoplastic cells which have been associated with genomic instability and altered gene expression. Because epigenetic deregulation occurs early in carcinogenesis and is potentially reversible, intervention strategies targeting the epigenome have been proposed for cancer prevention. Bioactive food components (BFCs) with anticancer potential, including folate, polyphenols, selenium, retinoids, fatty acids, isothiocyanates and allyl compounds, influence DNA methylation and histone modification processes. Such activities have been shown to affect the expression of genes involved in cell proliferation, death and differentiation that are frequently altered in cancer. Although the epigenome represents a promising target for cancer prevention with BFCs, few studies have addressed the influence of dietary components on these mechanisms in vivo, particularly on the phenotype of humans, and thus the exact mechanisms whereby diet mediates an effect on cancer prevention remains unclear. Primary factors that should be elucidated include the effective doses and dose timing of BFCs to attain epigenetic effects. Because diet-epigenome interactions are likely to occur in utero, the impact of early-life nutrition on cancer risk programming should be further investigated.


Assuntos
Epigenômica , Neoplasias/genética , Neoplasias/prevenção & controle , Ciências da Nutrição , Medicina Preventiva/métodos , Animais , Anticarcinógenos/uso terapêutico , Butiratos/química , Metilação de DNA , Dieta , Epigênese Genética , Ácidos Graxos , Alimentos , Histonas/metabolismo , Humanos , Modelos Biológicos , Neoplasias/metabolismo , Polifenóis/química , Retinoides/química , Selênio/química
9.
Br J Nutr ; 103(6): 803-6, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19948078

RESUMO

Studies have shown that various antioxidants are decreased in different age-related degenerative diseases and thus, oxidative stress would have a central role in the pathogenesis of many disorders that involve neuronal degeneration, including Alzheimer's disease (AD). The present study aimed to assess the nutritional status of Se in AD patients and to compare with control subjects with normal cognitive function. The case-control study was carried out on a group of elderly with AD (n 28) and compared with a control group (n 29), both aged between 60 and 89 years. Se intake was evaluated by using a 3-d dietary food record. Se was evaluated in plasma, erythrocytes and nails by using the method of hydride generation atomic absorption spectroscopy. Deficient Se intake was largely observed in the AD group. AD patients showed significantly lower Se levels in plasma, erythrocytes and nails (32.59 microg/l, 43.74 microg/l and 0.302 microg/g) when compared with the control group (50.99 microg/l, 79.16 microg/l and 0.400 microg/g). The results allowed us to suggest that AD has an important relation with Se deficiency.


Assuntos
Doença de Alzheimer/sangue , Estado Nutricional , Selênio/sangue , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Dieta , Eritrócitos/química , Feminino , Humanos , Masculino , Unhas/química , Selênio/administração & dosagem , Selênio/análise , Espectrofotometria Atômica
10.
Acta Cir Bras ; 24(5): 377-82, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19851690

RESUMO

PURPOSE: To study farnesol (FOH) effects on liver regeneration after 70% partial hepatectomy (PH) in rats. METHODS: Animals received FOH (25 mg/100 g body weight/day) or corn oil (CO, 0.25 mL/100 g body weight/day, controls). After a 2 week-treatment, all animals were subjected to PH and euthanized at different time points (0 h, 0.5 h, 4 h, 8 h, 18 h and 24 h) after surgery. Hepatic cell proliferation (PCNA positive nuclei) and apoptosis (fluorescence microscopy) were evaluated. RESULTS: Compared to CO treatment, FOH treatment inhibited (p<0.05) cell proliferation at 24h (S phase of the cell cycle) after PH. This was preceded by an induction of apoptosis 0.5 h (p<0.05; G(0)/G(1) transition phase) after surgery. CONCLUSION: The results of the present study suggest that apoptosis induction could be associated with the reduced number of cells at the S phase observed in FOH group. These novel in vivo data reinforce FOH as a promising chemopreventive and therapeutic agent against cancer.


Assuntos
Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Farneseno Álcool/farmacologia , Hepatectomia/métodos , Regeneração Hepática/efeitos dos fármacos , Animais , Bovinos , DNA/biossíntese , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar
11.
Acta cir. bras ; 24(5): 377-382, Sept.-Oct. 2009. ilus, graf, tab
Artigo em Inglês | LILACS | ID: lil-529156

RESUMO

PURPOSE: To study farnesol (FOH) effects on liver regeneration after 70 percent partial hepatectomy (PH) in rats. METHODS: Animals received FOH (25 mg/100 g body weight/day) or corn oil (CO, 0.25 mL/100 g body weight/day, controls). After a 2 week-treatment, all animals were subjected to PH and euthanized at different time points (0 h, 0.5 h, 4 h, 8 h, 18 h and 24 h) after surgery. Hepatic cell proliferation (PCNA positive nuclei) and apoptosis (fluorescence microscopy) were evaluated. RESULTS: Compared to CO treatment, FOH treatment inhibited (p<0.05) cell proliferation at 24h (S phase of the cell cycle) after PH. This was preceded by an induction of apoptosis 0.5 h (p<0.05; G0/G1 transition phase) after surgery. CONCLUSION: The results of the present study suggest that apoptosis induction could be associated with the reduced number of cells at the S phase observed in FOH group. These novel in vivo data reinforce FOH as a promising chemopreventive and therapeutic agent against cancer.


OBJETIVO: Estudar o efeito do farnesol (FOH) durante a regeneração hepática em ratos submetidos à Hepatectomia Parcial (HP) a 70 por cento. MÉTODOS: Os animais foram tratados com FOH (25 mg/100g de peso corpórel/dia) ou óleo de milho (OM, 0,25 mL/100g de peso corpóreo/dia, grupo controle). Depois de 2 semanas de tratamento, todos os animais foram submetidos à HP e eutanaziados em diferentes momentos (0h, 30min., 4h, 8h, 18h, 24h.) após o procedimento cirúrgico. Foi avaliada a proliferação celular (imunohistoquímica para PCNA) e a apoptose (microscopia de fluorescência). RESULTADOS: Em comparação aos animais controles, animais tratados com FOH apresentaram menor (p<0,05) proliferação celular 24h. (fase S do ciclo celular) após a HP. Tal efeito foi precedido de uma indução de apoptose 30min. (p<0,05; transição entre as fases G0/G1 do ciclo celular) após a cirurgia. CONCLUSÃO: Os resultados do presente estudo sugerem que a indução da apoptose pode estar associada com o menor número de células na fase S observadas nos animais tratados com FOH. Essa nova evidência in vivo reforça o farnesol como um promissor agente preventivo e terapêutico contra o câncer.


Assuntos
Animais , Bovinos , Masculino , Ratos , Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Farneseno Álcool/farmacologia , Hepatectomia/métodos , Regeneração Hepática/efeitos dos fármacos , Modelos Animais de Doenças , DNA , Avaliação Pré-Clínica de Medicamentos , Distribuição Aleatória , Ratos Wistar
12.
Carcinogenesis ; 26(6): 1091-9, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15718255

RESUMO

Chemopreventive activities of the isoprenoids geranylgeraniol (GGO) and beta-ionone (BI) were evaluated during initial phases of hepatocarcinogenesis. Rats received 8 or 16 mg/100 g body wt GGO (GGO8 and GGO16 groups) or BI (BI8 and BI16 groups), or only corn oil (CO group, controls) daily for 7 weeks. Incidence (%) and the mean number of visible hepatocyte nodules/animal were inhibited in the GGO8 (64% and 21 +/- 40), GGO16 (33% and 3 +/- 5), BI8 (50% and 13 +/- 34) and BI16 (42% and 9 +/- 19) groups compared with the CO group (100% and 34 +/- 51) (P < 0.05, except for the GGO8 group). Number/cm(2) liver section, mean area (mm(2)) and % liver section area occupied by persistent hepatic placental glutathione S-transferase positive preneoplastic lesions (PNL) were reduced in the GGO8 (11 +/- 9; 0.26 +/- 0.35; 2.7 +/- 3.0), GGO16 (6 +/- 6; 0.18 +/- 0.16; 0.9 +/- 0.9), BI8 (9 +/- 5; 0.13 +/- 0.20; 1.1 +/- 1.2) and BI16 (8 +/- 6; 0.08 +/- 0.09; 0.6 +/- 0.4) groups compared with the CO group (26 +/- 18; 0.29 +/- 0.34; 7.0 +/- 5.5) (P < 0.05). GGO16 and BI16 groups showed smaller visible hepatocyte nodules, reduced PNL cell proliferation and total plasma cholesterol levels compared with the CO group (P < 0.05), but did not show any differences (P > 0.05) in PNL apoptosis. DNA damage expressed as comet length (microm) was reduced in the GGO8 (96.7 +/- 1.5), GGO16 (94.2 +/- 1.5), BI8 (97.1 +/- 1.1) and BI16 (95.1 +/- 1.5) groups compared with the CO group (102.1 +/- 1.7) (P < 0.05). In comparison with normal animals, the CO group animals showed increased (P < 0.05) nuclear levels of nuclear factor kappa B (NF-kappaB) p65 subunit in hepatic cells, which were decreased (P < 0.05) in the GGO16 group animals. Anticarcinogenic actions of these isoprenoids seem to follow a dose-response relationship. Results indicate that GGO and BI could be represented as promising chemopreventive agents against hepatocarcinogenesis. Inhibition of cell proliferation and DNA damage seems to be important for the anticarcinogenic actions of isoprenoids, while the inhibition of NF-kappaB activation seems to be specifically related to GGO actions.


Assuntos
Anticarcinógenos/farmacologia , Colesterol/sangue , Dano ao DNA/efeitos dos fármacos , Diterpenos/farmacologia , Neoplasias Hepáticas Experimentais/prevenção & controle , NF-kappa B/antagonistas & inibidores , Norisoprenoides/farmacologia , Animais , Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Óleo de Milho , Ativação Enzimática/efeitos dos fármacos , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Neoplasias Hepáticas Experimentais/patologia , Masculino , NF-kappa B/metabolismo , Lesões Pré-Cancerosas/patologia , Lesões Pré-Cancerosas/prevenção & controle , Ratos , Ratos Wistar , Fator de Transcrição RelA
13.
Nutr Cancer ; 50(1): 101-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15572303

RESUMO

The eventual chemopreventive effect of squalene (SQ), a triterpene present in olive oil, was evaluated when administered to Wistar rats during a period comprising the initiation and selection/promotion of the "resistant hepatocyte" (RH) model of hepatocarcinogenesis. During 8 consecutive wk, animals received by gavage SQ (100 or 150 mg/100 g body weight) dissolved in corn oil (CO) daily. Animals treated with only CO and submitted to the RH model were used as controls. Treatments with SQ did not result in inhibition of macroscopically visible hepatocyte nodules (P > 0.05) or of hepatic placental glutathione S-transferase- positive preneoplastic lesions (PNL; P > 0.05). Hepatic cell proliferation and apoptosis indexes were not different (P > 0.05) among the different experimental groups, both regarding PNL and surrounding normal tissue areas. There were no significant differences (P > 0.05) among comets presented by rats treated with the two SQ doses or with CO. On the other hand, SQ increased total plasma cholesterol levels when administered at both doses (P < 0.05). This indicates that the isoprenoid was absorbed. Thus, SQ did not present chemopreventive activity during hepatocarcinogenesis and had a hypercholesterolemic effect, suggesting caution when considering its use in chemoprevention of cancer.


Assuntos
Quimioprevenção/métodos , Colesterol/sangue , Neoplasias Hepáticas Experimentais/prevenção & controle , Esqualeno/farmacologia , Administração Oral , Animais , Apoptose/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Quimioprevenção/efeitos adversos , Colesterol/metabolismo , Ensaio Cometa , Óleo de Milho/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Absorção Intestinal , Masculino , Azeite de Oliva , Óleos de Plantas/farmacologia , Lesões Pré-Cancerosas/patologia , Distribuição Aleatória , Ratos , Ratos Wistar , Esqualeno/efeitos adversos , Esqualeno/farmacocinética
14.
In. Penteado, Marilene De Vuono Camargo. Vitaminas: aspectos nutricionais, bioquímicos, clínicos e analíticos. Barueri, Manole, 2003. p.551-604.
Monografia em Português | LILACS | ID: lil-342956
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA